Hormone Therapy May Enhance Weight Loss Benefits of GLP-1 Drugs in Women

Study Overview

A new study indicates that hormone therapy could amplify the weight-loss effects of GLP-1 medications such as Ozempic and Zepbound for women undergoing menopause. This research is set to be presented at the annual meeting of The Menopause Society.

Research Findings

The study involved approximately 3,900 women, with around 2,400 using semaglutide (Ozempic/Wegovy) and nearly 1,500 on tirzepatide (Mounjaro/Zepbound). According to the lead researcher, Dr. Regina Castaneda from the Mayo Clinic Florida, this represents one of the largest examinations of the connection between GLP-1 drugs and hormone therapy.

Women in the study were all aged 45 and older, averaging 57 years old. All participants had a BMI categorized as overweight to obese.

Over the course of the study, those who combined hormone therapy with semaglutide experienced notable weight loss. For instance, at one year, participants on both treatments lost approximately 11% of their total body weight on average, compared to a 9.5% loss among those using only semaglutide.

Additionally, 22% of women using the hormone and semaglutide combination achieved a weight loss of 20% or more, compared to 18% in the semaglutide-only group. Furthermore, 6% of combo users lost 30% or more of their total body weight, in contrast to 4% for those solely on semaglutide.

Tirzepatide Results

Tirzepatide also demonstrated improved outcomes when paired with hormone therapy, although not to the extent of semaglutide. At the three-month mark, those combining tirzepatide with hormone therapy achieved a weight loss of 6.6%, compared to 5.9% for those on tirzepatide alone.

This combination also saw a higher percentage of participants lose at least 5% of their total body weight (88% vs. 84%).

Significance of the Findings

Dr. Castaneda noted that the stronger effects observed with semaglutide may point to specific interactions with GLP-1 signaling and estrogen. However, she stressed the necessity of more research to validate these findings further.

While this study offers promising insights, it is crucial to recognize that weight loss is not an approved indication for hormone therapy. The Menopause Society highlighted that menopausal women often face weight gain challenges and have increasingly turned to GLP-1 drugs for assistance. Notably, one in five women aged 50 to 64 are or have used a GLP-1 medication, making it a significant demographic.

Implications for Black Women

Obesity disproportionately impacts Black women, particularly during menopause, when hormonal changes complicate weight management. As estrogen and progesterone levels decline, issues like abdominal fat accumulation and increased insulin resistance often arise.

This research is especially pertinent for Black women, as enhanced efficacy of GLP-1 drugs could mitigate some health risks linked to obesity.

Future Directions

Clinical trials remain essential for expanding knowledge about menopause management and related health issues. Current research focuses include:

• Menopause symptom management
• Weight loss strategies
• GLP-1 medication studies
• Hormone therapy exploration
• Heart health during menopause

Increased participation from diverse populations in clinical research can enhance our understanding of how treatments work across different demographics. Historically underrepresented, Black Americans' involvement in studies is crucial for uncovering how various therapies might benefit diverse groups.

To learn more about clinical trials and their potential benefits, visit BlackDoctor’s Clinical Trials Resource Center.